SOP Non-Adherence in QC Labs: Global Audit Trends SOP Non-Adherence in QC Labs: Global Audit Trends Ensuring compliance with Standard Operating Procedures (SOPs) in Quality Control (QC) laboratories is a critical aspect of Good Manufacturing Practice (GMP). Non-adherence to SOPs can lead to significant regulatory scrutiny and negatively impact the integrity of data and product quality. This article examines trends in SOP non-adherence observed during GMP audits, providing a comprehensive guide for professionals in quality assurance (QA), quality control (QC), validation, regulatory, manufacturing, and clinical pharmacovigilance. It will also touch on Out of Specification (OOS) findings and OOS investigations. Understanding…

Laboratory Equipment Qualification Failures: Compliance Roadmap 2023 Laboratory Equipment Qualification Failures: Compliance Roadmap 2023 Laboratory equipment qualification is a critical component of ensuring the reliability and validity of data generated in compliance with regulatory requirements. Failure to appropriately qualify laboratory equipment can lead to significant regulatory non-compliance, resulting in audit findings that may impact product quality and patient safety. This tutorial will delve into the step-by-step approach to understanding, addressing, and preventing laboratory equipment qualification failures, aligning with FDA, EMA, and ICH guidelines. Understanding Laboratory Equipment Qualification Laboratory equipment qualification is a systematic process that involves establishing documented evidence that…

CDSCO Stability Testing Audit Findings in Indian Pharma Plants CDSCO Stability Testing Audit Findings in Indian Pharma Plants The regulatory landscape for pharmaceutical stability testing is critical to ensuring product efficacy and safety. The Central Drugs Standard Control Organization (CDSCO) in India has consistently reinforced this principle through its stringent audit procedures. This guide aims to explore the key findings from CDSCO stability testing audits in Indian pharma plants, with an emphasis on GMP audit findings. We will also cover the implications these findings have on Quality Control (QC) audits and Out-of-Specification (OOS) investigation protocols, as well as suggest corrective…

EU GMP Annex 15 Laboratory Inspection Observations Explained EU GMP Annex 15 Laboratory Inspection Observations Explained In the highly regulated landscape of pharmaceutical and biopharmaceutical industries, adherence to Good Manufacturing Practices (GMP) is crucial. This is particularly true when it comes to laboratory inspections, where findings can directly impact product release and patient safety. The EU GMP Annex 15, which deals with qualification and validation, offers essential guidelines for ensuring that laboratory processes are compliant. This article will explore EU GMP Annex 15 laboratory inspection observations, potential GMP audit findings, and provide guidance on effective corrective and preventive actions (CAPA)…

FDA QC Laboratory Warning Letters: Common Mistakes and CAPA FDA QC Laboratory Warning Letters: Common Mistakes and CAPA Quality Control (QC) laboratories are critical to ensuring the safety, efficacy, and quality of pharmaceuticals. The FDA conducts inspections to assess compliance with Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP). This article provides a detailed step-by-step tutorial focusing on common mistakes identified in FDA 483 audit findings, associated warning letters, and guidance on Corrective and Preventive Actions (CAPA). Understanding FDA 483 Audit Findings FDA 483 audit findings are reports issued when an FDA inspector observes any conditions that may violate…